Glaucoma Origins May Lead Potential Cure
Main Category: Eye Health / BlindnessArticle Date: 19 Jan 2012 - 0:00 PST
| Patient / Public: | ![]() |
4 (1 votes) |
| Healthcare Prof: | ![]() |
4 (1 votes) |
| Article Opinions: | 2 posts |
Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent.
New findings at Georgia Tech, published in January during Glaucoma Awareness Month, explore one of the many molecular origins of glaucoma and advance research dedicated to fighting the disease.
Glaucoma is typically triggered when fluid is unable to circulate freely through the eye's trabecular meshwork (TM) tissue. Intraocular pressure rises and damages the retina and optic nerve, which causes vision loss. In certain cases of glaucoma, this blockage results from a build-up of the protein myocilin. Georgia Tech Chemistry and Biochemistry Assistant Professor Raquel Lieberman focused on examining the structural properties of these myocilin deposits.
"We were surprised to discover that both genetically defected as well as normal, or wild-type (WT), myocilin are readily triggered to produce very stable fibrous residue containing a pathogenic material called amyloid," said Lieberman, whose work was published in the most recent Journal of Molecular Biology.
Amyloid formation, in which a protein is converted from its normal form into fibers, is recognized as a major contributor to numerous non-ocular disorders, including Alzheimer's, certain forms of diabetes and Mad Cow disease (in cattle). Scientists are currently studying ways to destroy amyloid fibrils as an option for treating these diseases. Further research, based on Lieberman's findings, could potentially result in drugs that prevent or stop myocilin amyloid formation or destroy existing fibrils in glaucoma patients.
Until this point, amyloids linked to glaucoma had been restricted to the retinal area. In those cases, amyloids kill retina cells, leading to vision loss, but don't affect intraocular pressure.
"The amyloid-containing myocilin deposits we discovered kill cells that maintain the integrity of TM tissue," said Lieberman. "In addition to debris from dead cells, the fibrils themselves may also form an obstruction in the TM tissue. Together, these mechanisms may hasten the increase of intraocular pressure that impairs vision."
Visit our eye health / blindness section for the latest news on this subject.
The National Institutes of Health (award number R01EY021205 from the National Eye Institute) funded the research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Eye Institute or the National Institutes of Health.
Georgia Institute of Technology
MLA
23 Feb. 2012. <http://www.medicalnewstoday.com/releases/240449.php>
APA
http://www.medicalnewstoday.com/releases/240449.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (2)
Iron In Amyloid
posted by Tom Hennessy on 19 Jan 2012 at 7:22 amIron has been linked to amyloid.
"Redox-active iron mediates amyloid-beta toxicity"
Could? a lack of blood flow mediate iron deposition which induces myocilin , much like a plant produces penicillin in response to iron ?
GLAUCOMA REASONS WITH CURE
posted by TANVIR on 20 Jan 2012 at 6:46 pmAFTER COMPLETE RESEARCH ABOUT MYOCILIN/AMYLOID IT WILL BE A GREAT ACHIEVEMENT TO AVOID DEVELOPMENT & THEN TREATMENT OF GLAUCOMA.IT WOULD BE A GREAT ACHIEVEMENT FOR THOSE POOR WHO ARE AT GREAT RISK OF DEVELOPING GLAUCOMA.MAY GOD HELP ALL OF US TO SERVE THE HUMANITY.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




